Attorney General Drew Wrigley of North Dakota has called on consumers to verify their eligibility for compensation related to specific generic drug purchases. This initiative follows the pursuit of preliminary approval for a $39.1 million settlement with Apotex by 50 states and territories. The settlement aims to address a conspiracy by Apotex to inflate drug prices and restrict competitors.
This action is part of a broader settlement strategy announced last fall, which also included a $10 million agreement with Heritage Pharmaceuticals. In the latest development, all necessary signatures for the Apotex settlement have been secured. The settlement was filed in a U.S. District Court in Hartford, Connecticut.
The period for eligible drug purchases spans from May 2009 to December 2019. For information on eligibility for compensation, consumers can contact toll-free at 1-866-290-0182, email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com.
The settlements with Apotex and Heritage settle allegations of manipulating drug prices, reducing market competition, and restraining trade for several generic drugs. Both companies agreed to cooperate in ongoing litigation against 30 corporate defendants and 25 individual executives. They have also committed to reforms aimed at promoting fair competition and antitrust law compliance.
Since 2016, North Dakota has been part of a coalition of states and territories filing multiple antitrust complaints. These complaints detail conspiracies that resulted in artificially high drug prices and promoted collaboration among drug manufacturers to sustain these practices.
“We are working hard to return money to North Dakota consumers who paid too much for their medications because of the collusion and conspiracies in some segments of the pharmaceutical industry,” stated Wrigley. He urged North Dakotans to assist in identifying eligible individuals for compensation following the alleged overpricing.
###
